Floatz logo

Semaglutide

Bipolar II Disorder

Mayo Clinicprotein_peptidePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Bipolar II Disorder cohort.

Asset / SponsorPhaseRating
Lurasidone
Massachusetts General Hospital
Phase 4BBB
Valproic Acid
National Cheng-Kung University Hospital
Phase 4BB
Seroquel®
First Affiliated Hospital of Zhejiang University
Phase 4BB
VENLOR
Stanley Medical Research Institute
Phase 4BB
LITHIUM, ELEMENTAL
Brigham and Women's Hospital
Phase 4BB

View all 37 →

Same molecule, other indications

Semaglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
81 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →